BioAtla, Inc. (BCAB) Stock Forecast
BCAB analyst forecast
as of October 21, 2026- Analyst consensus
- Buy 4.25 / 5 from 4 analysts
- Price target
- $10.00 average of analyst targets
- Upside to target
- +637.5% from the latest close
- Next earnings
- —
- 52-week range
- $1.08 – $61.00
BCAB analyst ratings
4 analystsNumber of analysts at each rating.
BCAB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BCAB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$1.34 | −$1.84 | −$0.81 | −$1.38 | +2.9% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BCAB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | — |
BCAB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BCAB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$1.61 | −$1.60 | −$1.60 | −$1.60 | −$1.34 | −17.2% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BCAB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BCAB beat in 10 of 11.
What analysts expect from BCAB
4 analysts cover BioAtla; their consensus rating is buy (4.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.00, 637.5% above the latest close of $1.36. For 2026 the average estimate is −$1.34 per share. BioAtla beat the EPS estimate in 10 of the last 11 quarters.
Related: BCAB income statement, BCAB key metrics, BCAB chart. See the BCAB stock overview for the latest quote and news.
BCAB forecast FAQ
What is BioAtla's price target?
The average analyst price target for BioAtla is $10.00, 637.5% above the latest close of $1.36.
Is BioAtla a buy, hold or sell?
Of 4 analysts covering BioAtla, 2 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
Does BioAtla usually beat earnings estimates?
BioAtla reported EPS at or above the analyst estimate in 10 of the last 11 quarters.